Name: Evaluatie van een model voor coloproctitis-colorectale kanker (UC-CRC) ulcerosa en werkzaamheid van Liujunzi-afkooksel (LJZD)
Uploaded: 2023-10-13T12:50:00
Description: Watch this Scientific Journal Video about Evaluation of an Ulcerative Coloproctitis-Colorectal Cancer UC-CRC Model and Efficacy of Liujunzi Decoction LJZD at JoVE.com

evaluation of an ulcerative coloproctitis-colorectal cancer (uc-crc) model and efficacy of liujunzi decoction (ljzd)

Liujunzi Afkooksel: een effectieve behandeling voor UC-CRC-preventie

Colorectal cancer (CRC) is a common gastrointestinal malignancy, the third most common malignancy, and the second most common cause of death in the world, accounting for 10% of the global cancer incidence and 9.4% of the total cancer-related death1,2. Genetic factors, chronic inflammation, high-fat diet, diabetes, and abnormal intestinal flora are risk factors for CRC3,4. Among them, inflammatory bowel disease, especially ulcerative coloproctitis (UC), is a clear risk factor for CRC5,6. UC-associated CRC (UC-CRC) is a transition process of inflammation, atypical hyperplasia, and cancer based on chronic inflammation of the colorectum, which is different from the typical adenoma-adenocarcinoma development model of CRC7,8. Compared with the general population, the risk of CRC is approximately 10-40 times higher in patients with inflammatory bowel disease9.
Currently, surgery is still the standard treatment for CRC, and depending on the location and stage of the tumor, radiation therapy, systemic drug therapy, or a combination of both are possible10. Although these traditional treatment modalities have made great progress, due to the high heterogeneity and recurrence rate of CRC, the prognosis is poor, and the treatment effect is not ideal11,12. Therefore, early detection, early diagnosis, and comprehensive treatment are key to improving the survival rate of CRC patients, and it is particularly important to pay attention to the transformation of UC to CRC. Over the years, traditional Chinese medicine (TCM) has attracted much attention in the treatment of UC-CRC or chronic gastritis due to its limited side effects and significant efficacy. Based on dialectical treatment, famous Chinese medicine practitioners of various generations have created a large number of classic prescriptions, such as Huangqi Jianzhong decoction13, Sijunzi decoction14, and Sishen pill15.
Liujunzi decoction (LJZD) originated from the works of Yi Xue Zheng Zhuan compiled in the Ming Dynasty and is a classic prescription in TCM16. As shown in Table 1, LJZD consists of six traditional herbs, including Codonopsis pilosula (Franch.) Nannf. (Dangshen), Poria cocos (Schw.) Wolf (Fuling), Atractylodes macrocephala Koidz. (Baizhu), Glycyrrhiza uralensis Fisch. (Gancao), Citrus reticulata Blanco (Chenpi) and Pinellia ternata (Thunb.) Breit (Banxia), which has the effect of replenishing qi and strengthening the spleen, drying dampness, and resolving phlegm. In modern clinical practice, it is often used to treat chronic gastritis, gastric ulcers, and duodenal ulcers. Modern pharmacological research has shown that LJZD and modified LJZD have high application value in the adjuvant treatment of UC and digestive tract cancer17,18,19.
At present, there are many ways to construct UC-CRC mouse models, but the azoxymethane (AOM)/dextran sulfate sodium (DSS) induced mouse model is the most widely used UC-CRC model; the clinical symptoms, morphological, and pathological observations have proved that the model is very similar to human UC-CRC20,21. The basic principle is to first induce carcinogenesis with chemical carcinogen AOM and then continuously expose mice to the inflammatory stimulation environment of DSS to simulate the continuous damage and repair of intestinal mucosal epithelium, thereby constructing a UC-CRC mouse model22. The aim of this study is to establish a mouse model of UC-CRC by intraperitoneal injection of AOM and cyclic stimulation of DSS in the short term and to evaluate the effect of the drug and the molecular mechanism of LJZD on UC-CRC in order to provide a scientific basis for the treatment of UC-CRC.

Auteur in de schijnwerpers: Liujunzi-afkooksel als een traditionele Chinese behandeling voor Coloproctitis-kanker

Vaststelling van een coloproctitis-kankermodel bij muizen en evaluatie van het therapeutisch effect van de Chinese geneeskunde

This study was on the prevention and treatment of coloproctitis cancer with traditional Chinese medicine. We aim to establish a mouse model for coloproctitis cancer and evaluate traditional Chinese medicine indicators. We confirmed that the Chinese medicine Liujunzi decoction is a effective treatment for coloproctitis cancer prevention.In the future, we will work to identify more sensitive biomarkers for colon and rectal cancer and screen Liujunzi decoction for therapeutic targets.

Watch this Scientific Journal Video about Evaluation of an Ulcerative Coloproctitis-Colorectal Cancer UC-CRC Model and Efficacy of Liujunzi Decoction LJZD at JoVE.com

Evaluatie van een model voor coloproctitis-colorectale kanker (UC-CRC) ulcerosa en werkzaamheid van Liujunzi-afkooksel (LJZD)

Stel om te beginnen het UC-CRC-muismodel op en dien de voorbereide LJZD- en 5-ASA-oplossing toe aan de respectievelijke groepen. Controleer na de medicamenteuze behandeling dagelijks het gewicht van muizen vanaf het begin van adaptieve voeding tot het einde van de medicamenteuze behandeling. Observeer en documenteer ijverig de fecale consistentie van elke experimentele muis en categoriseer deze als normaal, dunne ontlasting of waterige diarree.Documenteer zorgvuldig elke fecale bloeding die bij de proefdieren is waargenomen en categoriseer deze in geen bloeding, minimale bloeding of zichtbaar bloed in de ontlasting. Om het colorectale weefsel te scheiden, houdt u de geëuthanaseerde muizen in een cryogene anatomische omgeving. Zet de muizen in rugligging vast.Knip met een schaar het haar in de onderbuik en steriliseer het gebied met ethanol. Pak met een ooglidtang voorzichtig het snijpunt tussen de twee dijwortels en de buikmiddellijn vast. Gebruik vervolgens een schaar om een dwarsincisie van één tot 1,5 centimeter lang te maken.Voer een longitudinale incisie uit langs de mediaanlijn van de buik, beginnend vanaf het middelpunt van de transversale incisie tot aan de processus xiphoid. Maak de pericolorectale weefsels voorzichtig los in de richting van de anus en scheid het colorectum van het omringende weefsel. Duw de buikhuid voorzichtig opzij om het colorectum volledig bloot te leggen.Haal met een ooglidtang het colorectum uit de buikholte en snijd het van de anus naar de blindedarm. Bewaar de verzamelde colorectale weefsels in zoutoplossing bij vier graden Celsius. De UC-CRC-modelgroep had een significant gewichtsverlies in vergelijking met de controlegroep, dat werd verlicht door LJZD-behandeling.Behandeling met LJZD verbeterde de ziekteactiviteitsindex in vergelijking met de UC-CRC-modelgroep.

Research

JoVE Journal

Medicine

Evaluation of an Ulcerative Coloproctitis-Colorectal Cancer (UC-CRC) Model and Efficacy of Liujunzi Decoction (LJZD)

Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine

Colorectal cancer (CRC) is a common malignancy of the digestive system and has become the third most common malignancy worldwide and the second leading ...